Dr Animesh Saha

Menu

Research

Dr Saha participated actively in clinical research

Research activities at Tata Medical center- Apart from participation in the projects already mentioned in publication section. He was involved in other research activities, for example:

  • Can daily image guidance be avoided for Helical Tomotherapy in Head and neck Cancers? A prospective validation of an offline image guidance protocol (F5 Study) – Principal investigator.
  • Hypo-fractionated radiotherapy schedule of 35Gy in 10 Fractions in advanced incurable breast cancer: a prospective Phase I/II study (HYPORT study) – Co-investigator.
  • “A Phase III Randomised, Double-Blind, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB3 (proposed trastuzumab biosimilar) and Herceptin® in Women with Newly Diagnosed HER2 Positive Early or Locally Advanced Breast Cancer in Neoadjuvant Setting”( SB3-G31-BC study) – Co-investigator.
  • A phase IV, multicenter, open-label, single-arm study of Pertuzumab ( in combination with trastuzumab and docetaxel) in first line treatment of Indian patients with HER2- positive advanced ( metastatic or locally recurrent ) breast cancer ( ML29282 study) – Co-investigator.

Research activity in St James’s University Hospital as a MTI-

  • He set up the master excel sheet for data collection and collected data in an Audit of ‘Pattern of failure after Intensity modulated radiotherapy in head & neck squamous cell carcinoma using volumetric clinical target volume delineation’.
  • Worked as a sub investigator in clinical trials like ‘PLATO’, ‘RADICALS’ and ‘Aristotle’
  • He has done contouring of normal brain structures in both CT scan and MRI dataset for 10 patients helping Emily Johnstone (PhD student) on her project of developing normal brain structure contouring atlas.

Research activity in St James’s University Hospital as a Consultant-

  • He has set up the master excel sheet, collected & organised the data, analysed the data in an audit entitled ‘Can dosimetry affect overall survival in patients with medically inoperable peripheral early stage lung cancer treated with Stereotactic Ablative Radiotherapy (SABR)? – An analysis of 1300 patients’. The abstract has been presented in ASTRO 2019.
  • He has worked as an sub-investigator in the following trails:
  • A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)
  • Addition of stereotactic body radiotherapy to systemic chemotherapy in locally advanced biliary tract cancers (ABC07 trial)
  • A randomised trial of COnventional care versus Radioablation (stereotactic body radiotherapy) for Extracranial oligometastases (CORE trial)
  • ETOP/IFCT 4-12 STIMULI trial which is an Open-label, randomised, two-arm, phase II trial looking into addition of Immunotherapy with Nivolumab and Ipilumumab to standard of care in limited stage Small cell lung carcinoma.
  • A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)
  • GO40241 Phase III randomized, double-blind, placebo-controlled study (Neoadjuvant early stage resectable NSCLC) –Impower030 trial.
  • Stereotactic Ablative Radiotherapy for Oligometastatic Non-small cell lung cancer: A randomised phase III trial (SARON study)
  • A multi-centre randomised study of induction chemotherapy followed by capecitabine(+/-nelfinavir) with high or standard dose radiotherapy for locally advanced nonmetastatic pancreatic cancer (SCALOP 2 study)
  • A Randomised Phase II trial of standard versus dose escalated radiotherapy in the treatment of pain in malignant pleural mesothelioma. (SYSTEM 2 trial).
  • A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination with Platinum Doublet Chemotherapy and Radiotherapy for Participants with Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-799).
  • A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) with or without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants with Metastatic Nonsquamous Non-small Cell Lung Cancer (LEAP-006).
  • Adjuvant Durvalumab/placebo following SABR for stage I/II medically inoperable NSCLC (PACIFIC 4 study).
  • Adjuvant Durvalumab following sequential chemotherapy and radiotherapy in patients with unresecatble stage III NSCLC (PACIFIC 6 study).